You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
[TRADE NAME] modified release tablet is indicated for the management of severe pain where:
Other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and
the pain is opioid-responsive; and
requires daily, continuous, long term treatment.,[TRADE NAME] modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,[TRADE NAME] modified release tablet is not indicated as an as-needed (PRN) analgesia.
The naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,[TRADE NAME] is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
[TRADE NAME] modified release tablet is indicated for the management of severe pain where:
Other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and
the pain is opioid-responsive; and
requires daily, continuous, long term treatment.,[TRADE NAME] modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,[TRADE NAME] modified release tablet is not indicated as an as-needed (PRN) analgesia.
The naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,[TRADE NAME] is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
[TRADE NAME] modified release tablet is indicated for the management of severe pain where:
Other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and
the pain is opioid-responsive; and
requires daily, continuous, long term treatment.,[TRADE NAME] modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,[TRADE NAME] modified release tablet is not indicated as an as-needed (PRN) analgesia.
The naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,[TRADE NAME] is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
[TRADE NAME] modified release tablet is indicated for the management of severe pain where:
Other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and
the pain is opioid-responsive; and
requires daily, continuous, long term treatment.,[TRADE NAME] modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,[TRADE NAME] modified release tablet is not indicated as an as-needed (PRN) analgesia.
The naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,[TRADE NAME] is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
